↓ Skip to main content

Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial

Overview of attention for article published in The Lancet, August 2005
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Citations

dimensions_citation
811 Dimensions

Readers on

mendeley
585 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
Published in
The Lancet, August 2005
DOI 10.1016/s0140-6736(05)67176-0
Pubmed ID
Abstract

In the treatment of severe malaria, intravenous artesunate is more rapidly acting than intravenous quinine in terms of parasite clearance, is safer, and is simpler to administer, but whether it can reduce mortality is uncertain.

Mendeley readers

The data shown below were compiled from readership statistics for 585 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 4 <1%
Brazil 3 <1%
Portugal 2 <1%
Belgium 2 <1%
Thailand 2 <1%
Kenya 2 <1%
India 2 <1%
Germany 1 <1%
Malaysia 1 <1%
Other 4 <1%
Unknown 562 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 103 18%
Student > Master 100 17%
Researcher 80 14%
Student > Ph. D. Student 70 12%
Other 54 9%
Other 115 20%
Unknown 63 11%
Readers by discipline Count As %
Medicine and Dentistry 237 41%
Agricultural and Biological Sciences 68 12%
Biochemistry, Genetics and Molecular Biology 52 9%
Pharmacology, Toxicology and Pharmaceutical Science 39 7%
Chemistry 27 5%
Other 85 15%
Unknown 77 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2022.
All research outputs
#1,364,167
of 20,765,300 outputs
Outputs from The Lancet
#10,056
of 38,845 outputs
Outputs of similar age
#5,013
of 83,618 outputs
Outputs of similar age from The Lancet
#58
of 274 outputs
Altmetric has tracked 20,765,300 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 38,845 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 64.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 83,618 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 274 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.